Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S.
Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...
The international formula was designed to deliver all the benefits of the US formula while meeting regulatory requirements ...